Interview with Jacques Servier, Founder, Servier France
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
Address: 22, Rue Garnier 92200 Neuilly sur Seine,France
Tel: +33 (0)1 55 72 60 00
Our entire activity is based on three key principles:
• Our chief principle, naturally, is to satisfy the needs of the physicians who prescribe our products and of the patients who benefit from them.
• Just as importantly, we want our research to contribute to the progress of medicine. Research to us is at least as vital as being an industry.
• Our third principle is all the more crucial as it is too often overlooked: it is that every person working for us should find fulfillment through and in what they do.
Figures
• Leading French independent pharmaceutical company
• Second French pharmaceutical company worldwide
• SERVIER is established in 140 countries
• 85% of SERVIER’s sales are achieved internationally
• Consolidated turnover for the 2007/2008 financial year: €3.7 billion
• More than 25% of SERVIER’s turnover is invested in Research and Development
• Worldwide workforce of over 20 000, including nearly 3 000 in Research and Development
• SERVIER contributes 29% of the trade surplus of France’s pharmaceutical industry
Osteoporosis
Diabetes
Cardiovascular
Venous Diseases
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales growth of more than EUR 350 (USD 392) million…
Christopher Cuniasse, managing director of Fagron France, sheds light on the specialty area of pharmaceutical compounding and its link with personalized medicine, noting the benefits it can deliver to health…
Éric Ducournau, global CEO of Pierre Fabre Group, the second largest dermo-cosmetic company worldwide and the third-largest French pharmaceutical laboratory, provides insights into the group’s on-going internationalization and its emerging…
Inventiva is a French clinical-stage biotech company focused on developing oral small molecule epigenetic modulators in therapeutic areas with high unmet medical needs such as fibrosis, lysosomal storage disorders and…
Inotrem is a French biotech company developing a novel approach to target inflammatory diseases based on the TREM-1 pathway. Its CEO, Dr Jean-Jacques Garaud explains why he decided to leave…
Anne-Laurence Sabatini, vice president of Cluster France, Canada & Benelux at LEO Pharma, discusses the transformation of the company and how this has trickled down to her cluster. Furthermore, she…
Phillipe Archinard CEO of Transgene shares insights on the latest technologies being developed by the gene therapy specialist, explains how France’s innovation landscape is improving, and highlights the current opportunities…
Olivier Laureau, global president of Servier Group, outlines the impact of recent acquisitions, the significance of Servier’s recently-opened commercial subsidiary in the US, the ongoing importance of France to the…
Stéphane Regnault, president of Vygon, shares how the company has grown in size and international footprint over the past several years as a leading domestic French medtech. Regnault goes on…
Brigitte Calles, newly appointed general manager of Ferring France discusses the important role the affiliate plays as a market leader in reproductive medicine & women’s health, gastroenterology and uro-oncology and…
Nicolas Chandellier, general manager of BD France, discusses the company’s historic positioning in France and how the organization has transformed to further act as a partner to the healthcare system…
Franck Cousserans, general manager of France and Belgium at Jazz Pharmaceuticals, highlights the company’s key products and the challenges of market access in France. Furthermore, he indicates the steps needed…
See our Cookie Privacy Policy Here
